Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex Gets Committee Nod For Juvenile Arthritis, But Safety Registry Urged

Executive Summary

Concerns about cardiovascular risks associated with COX-2 inhibitors continue to haunt Pfizer's Celebrex as FDA's Arthritis Advisory Committee asked for long-term safety data as a condition of celecoxib's approval for a pediatric indication

You may also be interested in...



Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results

The European Medicines Agency issues a formal review, even though the claim had been withdrawn, in order to discourage off-label use.

Graham Meta-Analysis Ultimately Positive For Celebrex, Bextra

FDA Office of Drug Safety Associate Director for Science & Medicine David Graham's controversial presentation of unpublished studies on the safety of COX-2 inhibitors ultimately benefited certain COX-2s and raised questions about others in the class during a joint FDA advisory committee review

Merck After Vioxx: No Merger, But No Big Near-Term Launches

Following Merck's decision to withdraw Vioxx from the market, an FDA approval of the follow-on COX-2 inhibitor Arcoxia is likely to be delayed

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel